These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 16911291

  • 1. Novel treatment of Sézary-like syndrome due to adult T-cell leukaemia/lymphoma with daclizumab (humanized anti-interleukin-2 receptor alpha antibody).
    Osborne GE, Pagliuca A, Ho A, du Vivier AW.
    Br J Dermatol; 2006 Sep; 155(3):617-20. PubMed ID: 16911291
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Treatment of Sézary syndrome with bexarotene after IFNalpha and methotrexate failure.
    Bagot M.
    Dermatol Clin; 2008 Jan; 26 Suppl 1():27-9. PubMed ID: 18405184
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Treatment of late-stage Sézary syndrome with 2-Chlorodeoxyadenosine.
    Bouwhuis SA, el-Azhary RA, McEvoy MT, Gibson LE, Habermann TM, Witzig TE, Pittelkow MR.
    Int J Dermatol; 2002 Jun; 41(6):352-6. PubMed ID: 12100691
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Successful treatment of refractory Sezary syndrome by anti-PD-1 antibody (nivolumab).
    Shen K, Liu Y, Cao X, Zhou D, Li J.
    Ann Hematol; 2017 Apr; 96(4):687-688. PubMed ID: 28120019
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Bexarotene monotherapy for patients with refractory Sézary syndrome.
    Staib G, Scharffetter-Kochanek K.
    Dermatol Clin; 2008 Jan; 26 Suppl 1():61-3. PubMed ID: 18405190
    [No Abstract] [Full Text] [Related]

  • 11. Successful treatment with daclizumab of refractory anaplastic lymphoma.
    Costa V, Oliva T, Norton L.
    Pediatr Blood Cancer; 2009 Dec; 53(6):1130-1. PubMed ID: 19598219
    [Abstract] [Full Text] [Related]

  • 12. Bexarotene combination therapy for patients with Sézary syndrome.
    Ranki A.
    Dermatol Clin; 2008 Jan; 26 Suppl 1():55-7. PubMed ID: 18405189
    [No Abstract] [Full Text] [Related]

  • 13. Systemic monoclonal antibody therapy (daclizumab) in the treatment of cicatrizing conjunctivitis in stevens-johnson syndrome, refractory to conventional therapy.
    Fiorelli VM, Dantas PE, Jackson AT, Nishiwaki-Dantas MC.
    Curr Eye Res; 2010 Dec; 35(12):1057-62. PubMed ID: 20929291
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Alemtuzumab in refractory Sézary syndrome.
    Reifs CM, Salido-Vallejo R, Garnacho-Saucedo GM, Corte-Sánchez S, González-Menchen A, García-Nieto AV.
    An Bras Dermatol; 2016 Dec; 91(5):642-644. PubMed ID: 27828640
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Daclizumab, an efficient treatment for steroid-refractory acute graft-versus-host disease.
    Bordigoni P, Dimicoli S, Clement L, Baumann C, Salmon A, Witz F, Feugier P.
    Br J Haematol; 2006 Nov; 135(3):382-5. PubMed ID: 16984386
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.